Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Thousand Oaks, USA
2659 Townsgate Road
Suite 236
Thousand Oaks, CA, 91361




Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression. Atara has three novel biologics in development, including PINTA 745 (Phase 2) for protein energy wasting in end-stage renal disease, STM 434 (IND-ready) for ovarian cancer and other solid tumors, and NINA 842 (pre-clinical) for cancer-related cachexia. Atara and its family of companies were launched in 2012 by a proven team of drug developers, Amgen, and Kleiner Perkins Caufield & Byers.

Recent Milestones



Atara Biotherapeutics screenshot
Above: Homepage
Uploaded: 12/17/13


  1. Atara Biotherapeutics Secures $38.5M in Series B Financing ( [edit]
  2. Atara Biotherapeutics Holds $13.5M Second Close of Series B FINANCING ( [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy